Semaphorin 7A: A novel marker of disease activity in Gaucher disease. Issue 5 (7th February 2020)

• Record Type: Journal Article
• Authors: Franco, Mélanie; Reihani, Nelly; Dupuis, Lucie; Collec, Emmanuel; Billette de Villemeur, Thierry; de Person, Marine; Moussa, Fathi; Berger, Marc G.; Belmatoug, Nadia; Le Van Kim, Caroline
• Is Part Of: American journal of hematology. Volume 95:Issue 5(2020:May)
• Page Start: 483
• Page End: 491
• Publication Date: 2020-02-07
• Subjects: Hematology -- Periodicals; 616.15
• DOI: 10.1002/ajh.25744
• Languages: English
• ISSNs: 0361-8609

Abstract

Abstract: Gaucher disease (GD) is a recessively inherited lysosomal storage disorder in which sphingolipids accumulates in the macrophages that transform into Gaucher cells. A growing body of evidence indicates that red blood cells (RBCs) represent important actors in GD pathophysiology. We previously demonstrated that altered RBC properties including increased Lyso‐GL1 levels, dyserythropoiesis, and iron metabolism defect in GD patients contribute to anemia and hyperferritinemia. Since RBC defects also correlated well with markers of GD severity and were normalized under enzyme replacement therapy (ERT), the identification of molecules that are deregulated in GD RBCs represents an important issue in the search of pertinent markers of the disease. Here, we found a decreased expression of the GPI‐anchored cell surface protein Semaphorin 7A (Sema7A) in RBCs from untreated GD (GD UT) patients, in parallel with increased levels of the soluble form in the plasma. Sema7A plays a role in neural guidance, atherosclerosis, and inflammatory diseases and represents a promigratory cue in physiological and pathological conditions. We showed that the decreased expression of Sema7A in RBCs correlated with their abnormal properties and with markers of GD activity. Interestingly, ERT restored the level of Sema7A to normal values both in RBCs and in plasma from GD patients. We then proposed that SemaA7A represents a simple and pertinent marker of inflammation in GD. Finally, because Sema7A is known to regulate the activity of immune cells, the increased level of soluble Sema7A in GD patients could propagate inflammation in several tissues.